Biofrontera Inc. (BFRI)

NASDAQ: BFRI · IEX Real-Time Price · USD
9.20
+0.65 (7.60%)
At close: Sep 22, 2023, 4:00 PM
9.02
-0.18 (-1.96%)
Pre-market: Sep 25, 2023, 8:02 AM EDT
7.6%
Market Cap 12.58M
Revenue (ttm) 29.05M
Net Income (ttm) -22.67M
Shares Out 1.37M
EPS (ttm) -17.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,956
Open 8.60
Previous Close 8.55
Day's Range 8.60 - 9.20
52-Week Range 7.40 - 25.80
Beta n/a
Analysts Strong Buy
Price Target 79.00 (+758.7%)
Earnings Date Nov 13, 2023

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts. [Read more]

Sector Healthcare
IPO Date Oct 29, 2021
Employees 81
Stock Exchange NASDAQ
Ticker Symbol BFRI
Full Company Profile

Financial Performance

In 2022, Biofrontera's revenue was $28.67 million, an increase of 18.98% compared to the previous year's $24.10 million. Losses were -$640,000, -98.30% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for BFRI stock is "Strong Buy." The 12-month stock price forecast is $79.0, which is an increase of 758.70% from the latest price.

Price Target
$79.0
(758.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products,...

27 days ago - Accesswire

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

WOBURN, MA / ACCESSWIRE / August 28, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces posi...

4 weeks ago - Accesswire

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

Conference call begins at 8:30 a.m. Eastern time today WOBURN, MA / ACCESSWIRE / August 11, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the comme...

6 weeks ago - Accesswire

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Trial Results Expected in Mid-2024 WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of derm...

6 weeks ago - Accesswire

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

WOBURN, MA / ACCESSWIRE / August 4, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ...

7 weeks ago - Accesswire

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year WOBURN, MA / ACCESSWIRE / July 13, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharm...

2 months ago - Accesswire

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, a...

2 months ago - Accesswire

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

WOBURN, MA / ACCESSWIRE / July 3, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, an...

3 months ago - Accesswire

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

WOBURN, MA / ACCESSWIRE / June 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, a...

3 months ago - Accesswire

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

WOBURN, MA / ACCESSWIRE / June 1, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, an...

4 months ago - Accesswire

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

WOBURN, MA / ACCESSWIRE / May 30, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, an...

4 months ago - Accesswire

Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects

Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDT WOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical com...

4 months ago - Accesswire

Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update

Conference call begins at 8:30 a.m. Eastern time today WOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commerci...

4 months ago - Accesswire

Biofrontera Inc. Announces Resignation of CEO

Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial Goals WOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:B...

4 months ago - Accesswire

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million

WOBURN, MA / ACCESSWIRE / May 11, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it has enter...

4 months ago - Accesswire

Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention

WOBURN, MA / ACCESSWIRE / May 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that as part of se...

4 months ago - Accesswire

Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023

WOBURN, MA / ACCESSWIRE / April 28, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will re...

5 months ago - Accesswire

Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)

WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the l...

5 months ago - Accesswire

Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce

WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is exec...

6 months ago - Accesswire

Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting

Providing live demonstrations of a PDT procedure using the RhodoLED® lamp at booth #2224 WOBURN, MA / ACCESSWIRE / March 17, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company speciali...

6 months ago - Accesswire

CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the...

7 months ago - Accesswire

Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

WOBURN, MA / ACCESSWIRE / March 8, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial resul...

7 months ago - Accesswire

Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023

WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35th A...

7 months ago - Accesswire

Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

WOBURN, MA / ACCESSWIRE / February 22, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will...

7 months ago - Accesswire

Biofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023

WOBURN, MA / ACCESSWIRE / February 15, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products has been invited to present ...

7 months ago - Accesswire